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Self-monitoring of blood glucose (SMBG) is an important tool to treat diabetes during pregnancy. However, proper
implementation of SMBG in pregnant women requires understanding of its applications and limitations. This article
reviews issues related to the implementation, efficacy, and accuracy of SMBG and discusses factors that can
confound results of SMBG during pregnancy.
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Perinatal morbidity and mortality rates, often affected by
maternal diabetes, have dramatically been reduced since
the discovery of insulin and its therapeutic implementation.
In addition to increased availability of insulin, many impor-
tant technological advances have been developed over the
preceding decades. These advances culminated in a larger
array of diagnostic and therapeutic capabilities that contri-
buted to improved outcomes in high-risk pregnancies.
The availability of glucose meters has represented an
important positive impact in the treatment of pregnant
women with any type of diabetes. Data frequently show
patients who perform self-monitoring of blood glucose
(SMBG) more strictly adhere to treatment programs due
to increased comprehension regarding treatment and
participation in the prescribed treatment regimen [1].
Indications for self-monitoring of blood glucose during
pregnancy complicated by diabetes
SMBG is an integral part of standard diabetes care [2].
It allows pregnant women and their healthcare provi-
ders to determine the most effective therapeutic mo-
dality (e.g. diet, physical activity, or insulin) to control
glucose levels and reduce risks of diabetes-related
complications. The number of daily tests required to
adequately monitor blood glucose levels is specific to
the patient and based on the recommendation of the* Correspondence: lenitazaj@gmail.com
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pregnant woman should be considered. For example, the
type of treatment (diet and/or insulin), frequency and in-
tensity of physical activity, and the risk of hypoglycemia.
Additionally, SMBG makes patients feel more secure and
comfortable using insulin since it allows early recognition
of symptoms of hypoglycemia [4].
The indications for, and frequency of SMBG in preg-
nant women that are not under insulin treatment must
be tailored to the individual. Patients must be trained to
adjust the amount of food intake with the frequency,
intensity, and timing of physical exercise. It is unclear
whether SMBG alone leads to improved glycemic con-
trol in non-insulin treated subjects with type 2 diabetes.
Additionally, there is no data in women with gestational
diabetes mellitus (GDM) [5].
Measured glucose values need to be frequently checked
to ensure both accuracy and the patient’s understanding
of any alterations to prescribed treatment. For the vast
majority of patients using insulin, SMBG is recommended
three or more times per day. A more intensive SMBG
regimen is indicated for women with pre-gestational type
1 or 2 diabetes. The aim is to reach adequate HbA1c levels
safely without inducing hypoglycemia [3,4].
When to monitor
Strict monitoring of postprandial glucose levels is para-
mount during pregnancy. Many studies have shown that
postprandial hyperglycemia beyond the 16th week of
pregnancy is the main predictor for fetal macrosomia
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mended to perform SMBG one hour after food intake
to evaluate potential adjustments in meal composition
and/or in the prandial insulin dose. In special circum-
stances, like women with slowed gastric emptying, a high-
fat meal, or women who use regular insulin for a prandial
bolus, it might be more appropriate to perform SMBG
two hours after meals instead of one. SMBG performed
before eating is the most useful parameter to identify opti-
mal basal insulin doses. Evaluating glycemic levels during
the night is recommended to diagnose and prevent noc-
turnal hypoglycemia [8].
One randomized study [6] of 66 women with GDM
observed better neonatal outcomes by aiming for 1-hour
postprandial glucose levels less than 140 mg/dL as opposed
to a preprandial target of 59 to 106 mg/dL. In another
study, 61 women with type 1 diabetes were randomly
assigned into two groups at 16 weeks gestation. Women
either monitored blood glucose levels preprandially or
postprandially. Postprandial capillary blood glucose moni-
toring significantly reduced the incidence of preeclampsia
and neonatal triceps skinfold thickness compared to pre-
prandial monitoring [9]. These studies have been criticized
for not using comparable target blood glucose levels for
pre- and post-prandial monitoring. Regardless, most spe-
cialists prefer postprandial testing at least partly, for the
physiologic changes discussed earlier.
Meter considerations
Diabetes education is paramount for proper use of glucose
meters and interpretation of measurements. Commercially
available glucose meters vary widely with respect to seve-
ral characteristics, such as: blood sample volume, size,
testing speed, memory capacity, type of technology ap-
plied, costs, and type of strips used [10]. All disposable
blood glucose meters function by one of two mechanisms:
reflectance (photometric) or electrochemical (ampero-
metric). Meters using reflectance measure a change in
color on the strip that occurs after an enzymatic reaction
with whole blood. Meters using electrochemical mecha-
nisms work with small volumes of blood to measure elec-
trochemical potential based on glucose oxidation [11].
Issues related to self-blood glucose monitoring during
pregnancy complicated by diabetes
Accuracy
Accuracy of a blood glucose meter reflects how closely
the measured value is to the actual value, while precision
describes the reproducibility of serial measurements and
is independent of the accuracy. For effective SMBG, it is
imperative that meters be both accurate and precise in a
series of values [12]. The best single measure of both ac-
curacy and precision is the mean absolute relative error
(MARE). MARE is calculated by taking the average forthe set of individual absolute errors relative to a refer-
ence value. For example, measured values of both 90
and 110 mg/dl are in error by 10% given a reference
value of 100 mg/dl [12].
The International Standards Organization (ISO), in
conjunction with international regulatory authorities,
healthcare providers, and device manufacturers, estab-
lished standards to evaluate accuracy of blood glucose
meters. ISO 15197 calls for a minimum accuracy where
95% of all measured values fall within 20% of reference
values above 75 mg/dl, and within 15 mg of glucose
values below 75 mg/dl [13]. According to the American
Diabetes Association, 5% of the values for glucose per-
formed with a given glucose meter should fall below
75 mg/dl for this meter be considered accurate. Accor-
ding to data currently available, the most accurate meter
today has only 63% acceptable values in the 5% inaccuracy
range [12]. Accordingly, it can be difficult for health care
providers and patients to assess the accuracy of blood glu-
cose monitoring systems. SMBG often presents significant
errors that are generally poorly understood by patients
and providers [14]. Healthcare providers can help patients
to obtain better results by identifying the source of errors
and methods for prevention and correction [12].
Inaccuracy of self-monitoring blood glucose during
pregnancy complicated by diabetes
The inaccuracy of SBGM during pregnancy comes from
four sources: strip factors, physical factors, patient factors,
and pharmacological factors.
Strip factors
Small strip-to-strip variation may lead to inaccuracy in
blood glucose readings. In some types of glucose strips,
the size of individual reaction wells and changes in en-
zyme coverage on the strips may influence reading accu-
racy [12]. Reduction of the mediator can cause problems
with the accuracy of electrochemical measurements. Nor-
mally, glucose is oxidized by glucose oxidase to form glu-
conic acid. The reduced form of glucose oxidase then
interacts with water and oxygen to form hydrogen pero-
xide. On a strip, the first step is identical, but in the sec-
ond step, the glucose oxidase pushes electrons to the
oxidized mediator, causing its reduction, rather than oxy-
gen plus water, forming hydrogen peroxide. The electrode
oxidizes the mediator, generating the glucose signal [12].
The oxidized mediator is somewhat unstable and sus-
ceptible to reduction, particularly at high temperatures,
which produces erroneously high blood glucose mea-
surements [15]. Blood glucose strips require complex
biochemical reactions to function properly, and have
finite lifetimes, usually about 2 years under ideal storage
conditions. Storing strips at high temperature or humi-
dity, or in an open vial (allowing the humidity to get to
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ferent brands of glucose strips fail differently. When a
failure occurs, some brands underestimate the glucose
values, whereas others overestimate. In both cases,
the error can be large, and usually meters are unable
to detect failed strips [12].
Physical factors
The most common physical factors that influence
the accuracy of blood glucose strips are altitude and
temperature [12].
Glucose oxidase biosensor strips are sensitive to oxy-
gen concentrations. The mediator and oxygen can both
compete as oxidants of the reduced form of glucose oxi-
dase. Since the electrode will only detect the mediator,
excess oxygen robs electrons from the active mediator
leading to underestimated glucose values. Conversely, at
lower oxygen concentrations, meters will overestimate
blood glucose levels. Consequently, glucose oxidase bio-
sensor strips are generally calibrated with capillary blood
and are most accurate when used with capillary blood.
Strips that use glucose dehydrogenase as the enzyme
are less affected by oxygen, and therefore are less
affected by altitude [12].
The influence of temperature is less predictable. Errors
presented at extreme temperatures are brand-specific
and not technology dependent. The errors may vary
from 5-7%, but can be either positive or negative [12].
Low temperatures decrease circulation to the skin. This
does not greatly influence glucose measured from a
fingertip since the arteriovenous shunts of the fingers
stay open. However, blood flow to the skin of the fore-
arm is dramatically decreased. Alternative site testing,
which normally has a lag of 15–30 min, can have a lag
of up to an hour when the arm is exposed to a very
low temperature [16].
Patient factors
The ability of a patient to use her meter properly can
greatly influence the accuracy of a blood glucose mea-
surement. Most blood glucose meters need to be coded.
Coding determines the relationship between the elec-
trical signal produced by the strip and the reported
blood glucose. Improper coding is one of the most com-
mon mistakes made by patients and the effect of mis-
coding is not uniform across all blood glucose ranges
[12]. Meters that do not require coding are more readily
available and are more accurate when used by patients.
Hematocrit abnormalities can also affect the results
obtained from SMBG. Hematocrit less than 30% may
overestimate blood glucose, while hematocrit greater
than 55% may underestimate measurements [17]. All
meters use whole blood concentration from capillaries.
When venous blood collected in laboratories, bloodglucose is measured with respect to plasma and not
whole blood. The density of erythrocytes causes glucose
content to be 10% to 15% lower in whole blood than in
plasma. However, most new meters convert whole-blood
results into plasma-calibrated results [10].
Plasma glucose levels in individuals with normal
hematocrit is 11% higher than in whole blood (venous
or capillary). The International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) recom-
mends expressing plasma glucose values rather than
whole blood values. Expression of plasma glucose values
facilitates comparison with measurements obtained by
laboratories. Plasma values can be obtained by multiplying
whole blood glucose concentration by 1.1. Many glucose
meters already convert blood values to plasma values. The
glucose meter manufacturer should expressly state whether
a meter automatically converts the whole blood measure-
ment to a plasma measurement.
SMBG devices are frequently updating styles, models,
and technologies. Systems are becoming more accurate
and easier for patients to use appropriately. Hand washing
has always been problematic, but because many newer
meters use microsamples, small amounts of contaminant
can greatly alter results [12]. Some substances that occur
naturally in the body can affect the accuracy of electro-
chemical blood glucose meters. These include triglyce-
rides, oxygen, and uric acid. High levels of triglycerides
cause underestimation of blood glucose by displacing glu-
cose in the capillary volume. Many pregnant women
present with high triglycerides levels, especially in the
third trimester, and this could lead to inaccuracy in their
SMBG values. Oxygen competes with the mediator to take
electrons from reduced glucose oxidase and high oxygen
values, such as those found in arterial blood or in patients
utilizing oxygen, will underestimate glucose values [12,18].
Low oxygen levels, in venous blood or patients with severe
chronic obstructive pulmonary disease may overestimate
glucose values. Extremely high levels of uric acid can give
incorrectly high values. Uric acid is only problematic in
patients with uric acid levels that are sufficient to induce
severe gout [12,19].
Glucose dehydrogenase is a less specific enzyme, so
some naturally occurring sugars can compete with glu-
cose. Galactose, xylose, and maltose compete with glucose
for glucose dehydrogenase binding sites and high levels of
these other sugars can cause overestimations of glucose
levels. However, glucose dehydrogenase sensors are less
sensitive to variations in oxygen concentration [20].
Pharmacologic factors
Many medications can affect the readings from SMBG.
With electrochemical glucose oxidase systems, acetamino-
phen, L-dopa, tolazamide, and ascorbic acid interact with
the electrode [19]. Fortunately, the error from these
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many other sugars can interfere. Maltose and xylose can
have a small effect, but icodextrin can have a tremendous
effect [21]. Icodextrin is used in some peritoneal dialysis
fluids and can increase glucose value reported by the
meter by more than 100 mg/dl. Meter manufacturers ge-
nerally do not disclose what substances interfere with
their specific product. However, doing so when possible
would improve accuracy of SMBG measurements by
patients and ultimate therapeutic efficacy.
Barriers to self-monitoring of blood glucose during
pregnancy
The first step towards a successful SMBG during preg-
nancy is patient education and an understanding of the
importance of SMBG to reducing complications during
and after pregnancy. The patient must be properly edu-
cated on all aspects of meter use. It is important she be
aware of how to properly code her meter, wash her
hands prior to the test, and to apply the correct amount
of blood to the test strip. It is also critical to educate
patients on how glucose from food can affect the test
results, to use test strips before the expiration date and
not longer than 90 days after the vial was opened. Lastly,
it is crucial to educate patients on proper storage of
strips and disposal of strips if they are subjected to ex-
treme humidity or temperature. Other common barriers
to SMBG include costs of the meters and strips, lower
socio-economic status, fewer HbA1c tests, obesity and
other comorbidities, poor glycemic control, stigmas of
testing in public places, pain, and inconvenience [4,22].
During pregnancy, relatively small changes in glucose
values may be clinically important. In clinical practice, it
is important to know how closely the glucose meter
readings can reflect the patient’s real plasma glucose
level. Perera et al. recently showed differences of up to
15% between SMBG and plasma glucose values. Varia-
tions of up to 15 mg/dl were found in pregnant women
with diabetes [23]. On the other hand, Kong et al. found
correlation between the SMBG and plasma glucose
levels in 90% of the measurements performed in women
with GDM that reached normoglycemia after dietary
treatment exclusively [24].
Conclusions
Treating hyperglycemia during pregnancy reduces adverse
pregnancy outcomes. The first step towards a tight glu-
cose control in pregnancy is patient adherence to SMBG.
There are several barriers and sources of errors associated
with SMBG. Pregnancy is a unique short period of time
when physicians, diabetes educators, and healthcare pro-
fessionals in general have the chance to provide informa-
tion and education about diabetes and SMBG. Specifically,
it is an opportunity to educate women on error preventionand correct interpretation of results. Additionally, they
can provide assistance to overcome barriers associated
with proper diabetes care and provide long-lasting benefits
to the mother and fetus.
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